BioNTech SE (B1NT34Q)

I am not going to pigeon hole them to specific timelines or dates. But they should have a strategy to raise awareness, improve presentation and have a professional approach to communication. They never wanted to be a penny stock and are developing an asset to potentially become the gold standard f

Another day….

Another week….

Another word-salad PR….

Another big, fat, juicy, KBLB nothingburger….

with a side order of lies….

https://i.imgflip.com/3bm6mk.jpg

SPX 60 min Chart. 60 min level Current Cycle Between Cycles (CCBC) 0 (Neutral). 60-E-2 (Overdue) confirmed at the close of the 5TH hour. Next possibilities: 60-S-1 (Extreme Overdue) 7399.80, 60-1 (Extreme Overdue) 7360.13, 60-E-1 7249.15 & 6TH UPRO Buy Signal.

https://investorshub.adv

SPX 60 min Chart. 60 min level Current Cycle Between Cycles (CCBC) 0 (Neutral). 60-E-2 (Overdue) confirmed at the close of the 5TH hour. Next possibilities: 60-S-1 (Extreme Overdue) 7399.80, 60-1 (Extreme Overdue) 7360.13, 60-E-1 7249.15 & 6TH UPRO Buy Signal.

https://investorshub.adv

I stick with my charts. HAWK

I follow my charts. When the chart changes I change. You have to be nimble to trade pennies. HAWK

*****BREAKING NEWS*****3RD DAY IN A ROW SHARE PRICE DIPS INTO 10s*****

Nice green close on a Friday. Time to ramp up for SUMMER MANIA soon ;)

brazen22,

Your concerns need to be dealing with how to disavow the check downs on bias done within the study. The regulators accepted or approved the SAP based on this check down on bias and JAMA Oncology published because even though mentioning possible sources of concern the check

Hey Lenny sell the place to a Data Centers they could at least put the water to good use.

Having an internal timeline is great.

Predicting what MHRA will do is clearly a problem.

I know you are not suggesting that NWBO predicted that the application was going to set the record for the longest, or one of the longest, applications in the history of the MHRA.

Or commitments on funding.

Lets goooooo!!!!!

Fair enough....like most OTC "investors" I definitely learned my lessons the hard way. Had a couple of good runners years ago that I held my entire position far too long. That was my mistake.

You are correct that the vast majority of pinks are pure junk and will crash at some point.

"Canary's HBAR ETF files to add staking..."

https://x.com/TokenRelations/status/2065479106527899775

"...What’s happening: On May 21, Canary Capital filed an updated prospectus for its Canary HBAR ETF, which it seeks to list on the Nasdaq. The update would permit the fun

Good use of AI prompts..

Probably 4 months+ after form10 and I think Respire could delay until say closer to IND.

I think folks need to spend some time conversing with AI to understand how valuable KRM-ll-81 can be and why a BP could salivate over such asset even befo

A little more than  3 weeks until the IDE decision. An approval will start human trials at the Mayo Clinic . IsoPet gaining traction . Over 1200% increase year over year . Let’s not forget the DCGI in India and the licensing potential of PrecisionGel .This share price won’t last . Neither will the b

Has nothing to do with Blag-O-Scammer.

Interesting



$166 ipo

And zero rhyme or reason...

Source...?

It could be SoftBank too.. they are looking to IPO AND ARE connected at the hip to sandbox

Pancreatic cancer is a death sentence. Most are found way too late. Had a friend who just passed. Had colon and then pancreatic.

🚀 NASDAQ2020’s buyout missing game,

Maxthedog

1-26-2026 ❌

jimr1717

July 27 2077

NASDAQ2020

November 5th 2021 ❌, 2022 ❌, 2023. ❌ ,2024 ❌ 2025 ❌ 2026, 2037, 2086

😅 Bears thought they had something here. This is ALL about the Form 7. Nothing else. They didn't file for June. 😵‍💫

While the CSE is eliminating the need for a form 7, it is not quite yet in effect. Simple oversight. Simple correction. OR ... believe what the R

RespireRx Pharmaceuticals Inc. is a leader in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatment options that address conditions affecting millions of people, but for which there are few or poor treatment options, includi